CN110133288A - Application of the neurofilament protein light chain in syphilis blood testing - Google Patents
Application of the neurofilament protein light chain in syphilis blood testing Download PDFInfo
- Publication number
- CN110133288A CN110133288A CN201910444151.9A CN201910444151A CN110133288A CN 110133288 A CN110133288 A CN 110133288A CN 201910444151 A CN201910444151 A CN 201910444151A CN 110133288 A CN110133288 A CN 110133288A
- Authority
- CN
- China
- Prior art keywords
- detection
- blood
- light chain
- cerebrospinal fluid
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to application of the neurofilament protein light chain in syphilis blood testing.Specifically, the kit includes the detection reagent for detecting blood neurofilament protein light chain level the present invention provides a kind of Lues Assay kit.The present invention also provides the application of the first detection reagent and optional second detection reagent in preparation detection kit for detecting blood neurofilament protein light chain, and second detection reagent is the detection reagent for detecting cerebrospinal fluid neurofilament protein light chain level, cerebrospinal fluid phosphorylated neurofilament ferritin heavy chain level etc..It is horizontal that the present invention is based on blood neurofilament protein light chains, for the early diagnosis of syphilis, parting by stages, therapeutic evaluation and/or prognosis evaluation provide it is reliable, facilitate and efficiently solution.
Description
The application be entitled " application of the neurofilament protein light chain in syphilis blood testing ", application No. is
The divisional application of the Chinese invention patent application of " 201810252711.6 ".
Technical field
The present invention relates to field of biomedicine technology, in particular to neurofilament protein light chain (NF-L) is in neurolues blood
Application in detection.
Background technique
Syphilis is popular on a large scale in China in the fifties in last century, strong in government with the establishment of new China
Control measure under, in Eradication syphilis in 1964.However since the eighties, the venereal disease including syphilis is again popular,
Since especially 2000, syphilis starts to propagate from people at highest risk to general population, and national Report of Syphilis disease incidence is passed in Class B
It ranked third position in catching an illness.The data statistics announced from Chinese Center for Disease Control and Prevention official is as it can be seen that in the past 10 years, the hair of syphilis
Sick rate is increasing year by year, and 12.80 (1/,100,000) from 2006 rise to 31.85 (1/,100,000) in 2015, is far from reality
Now eliminate the target of syphilis (referring to Fig. 1).Although the life quality of syphilitic obtains with the popularization and application of mould extract for treating
It is obviously improved, the death rate is remarkably decreased, and syphilis is still the Category B notifiable disease that attract great attention.
Syphilis is systemic, infectious diseases by caused one kind after microspironema pallidum intrusion human body.Microspironema pallidum is
A kind of small and very thin helical form microorganism, the mode of transverse division are bred, and are had in structure and are maintained spiral body elasticity
Axis fiber with buckling and can stretch, be conducive to microspironema pallidum and penetrate host tissue.Microspironema pallidum is not easy to give birth to out of the human body
It deposits, boiling death, the general disinfectant such as drying soap water and alcohol immediately can be easy to be killed, therefore at present not
Energy in vitro culture, microspironema pallidum can be reserved for the several years under low temperature (- 78 DEG C), be still able to maintain its form vigor and toxicity.Syphilis
Conveyor screw can limit the propagation and intrusion of microspironema pallidum being unable in vitro culture to a certain extent, but but also right
The research of microspironema pallidum and to the research of syphilis disease have caused great difficulties with it is constant, therefore syphilis is examined at present
Disconnected, treatment and prognostic study make little progress.
After microspironema pallidum invades human body, bred first in mucocutaneous infestation position, under formation primary syphilis is hard
Infantile malnutrition due to digestive disturbances or intestinalparasites, is that boundary clear, marginal swell, substrate be solid, Silent Neuritis round or ellipse superficial ulcer of cartilage sample hardness, and can
With groin or Ipsilateral enlargement of lymph nodes.If primary syphilis is not treated or treat not thorough, microspironema pallidum can pass through
Lymphatic system enters blood circulation, sends out to whole body, is clinically mainly shown as secondary syphilid, including macula, papule, purulence kitchen
Etc..Primary syphilis chancre and secondary syphilid all have self limiting, and generally leave no trace, if failing to treat or control
Treat it is unsuccessful, then enter the latent syphilis stage.Microspironema pallidum is in human body after lays dormant for years (2 years or more), to hiding
Organ cause different degrees of damage, can be involved nervous system, heart, bone, blood vessel etc., that is, enter tertiary syphilis.It needs
It is noted that existing research proves to separate microspironema pallidum, explanation after the cerebrospinal fluid of early syphilis patient is inoculated in animal
Microspironema pallidum is in intrusion human body early stage, it will be able to intrude into nervous system.
Neurolues is not each stage for only occurring in tertiary syphilis, but can betiding syphilis.Neurolues
Asymptomatic neurosyphilis (Asymptomatic Neurosyphilis), meninges syphilis (Meningeal can be divided into
Syphilis, including syphilitic meningitis and syphilis spinal pachymeningitis), meningovascular syphilis (Meningovascular
Syphilis), parenchymatous neurosyphilis (general paresis (general Paresis) and tabetic crisis (Tabes Dorsalis))
And gumme nerve syphilis.
It is positive that asymptomatic neurosyphilis refers to that the blood plasma of syphilis checks, cerebrospinal fluid presence is abnormal, but impassivity system
Sings and symptoms.O ' Leary's et al. the study found that 13.5% syphilitic's (including each syphilis stage) is asymptomatic
Neurolues, and Keidel et al. has found that 20% patient at least has a kind of brain in the research of primary syphilis and mesosyphilis
Abnormal (O ' Leary PA, Cole HN, Moore JE, the et al.Cooperative clinical studies in of spinal fluid
the treatment of syphilis:Asymptomatic neurosyphilis.Arch Derm Syphilol1937；
35:387–401；Keidel A,Moore JE.Studies in asymptomatic neurosyphilis I:A
tentative classification of early asymptomatic neurosyphilis.Arch Neurol
Psychiatry 1921；6:286–291y).12 to 18 months after infection usually occur for asymptomatic neurosyphilis, are nerves
The initial period of syphilis, asymptomatic neurosyphilis patient syphilitic more normal than cerebrospinal fluid are easier to have progressed to symptom nerve
Syphilis, therefore examination of cerebrospinal fluid should be carried out to suspicious patient, early treatment is found to early, and asymptomatic neurosyphilis is avoided to progress to
There is symptom neurolues.
Meninges syphilis includes syphilitic meningitis and syphilis spinal pachymeningitis, and 12 after taking place mostly in syphilis
In month, it can betide in 1.4% to 6% syphilitic, main cause is to fail in the early syphilis stage sufficiently to be treated.
Meningovascular syphilis includes cerebrovascular syphilis and spinal cord meningovascular syphilis, and nonspecific infection postsyphilitic 5 to 12 years
Occur, before the non-invention of antibiotic, 3.2% to 15% syphilitic can progress to meningovascular syphilis.
Parenchymatous neurosyphilis is the neurolues of relatively late period, including paralysis dementia and tabetic crisis.Paralysis dementia
Average latency is 15-20, it was reported that it is dull-witted that 5% syphilitic can progress to paralysis, and the paralysis of untreated
Dementia patients can be dead in 5 years.
Gumme nerve syphilis, it is rarer in neurolues, including brain gumme and spinal cord gumme, natural gum
The difference of swollen site of pathological change causes clinical manifestation also different, and brain gumme is mainly shown as that brain tumor similar to symptom, such as carries out
Nerve systemic symptom, epilepsy, increased intracranial pressure etc., MRI may occur in which the linear strain-hardening similar with meningioma.And spinal cord gumme
It can lead to quadriplegia when involving ceruical uertebra part, then can lead to paraparesis etc. when involving thoracic vertebrae.
Syphilis is referred to as greatest imitator, and the clinical manifestation of neurolues be also it is complicated and changeable, symptom is without special
Property, almost include all various symptoms and sign in neurology, may occur in which the sections such as neurology department, ophthalmology, dermatology, psychiatric department
Similar clinical manifestation, therefore to the misdiagnosis rate of neurolues height, misdiagnosis rate is strong up to blueness caused by 55.6%, such as neurolues
Year unknown cause cerebral infarction, epilepsy, disturbance of intelligence etc. occur in person between twenty and fifty may be by mistaken diagnosis, therefore, the correct diagnosis of neurolues
It is very important with timely treatment.
At present there is no the goldstandard for diagnosing neurolues, laboratory testing facilitates the diagnosis of neurolues；But simultaneously
There is no single detection method to can be used for the diagnosis of neurolues under all situations.The diagnosis of neurolues is tried dependent on blood plasma
It tests, cerebrospinal fluid (CSF) checks, the comprehensive analysis of nervous symptoms and sign.It is needed for there is the patient of neurolues clinical symptoms
It further to test.
Blood plasma test mainly includes that two classes are tested, i.e. non-syphilitic leptospira antigen plasma assay and TP antigen
Plasma assay.Non-syphilitic leptospira antigen plasma assay is to detect having instead in blood plasma to cuorin using cuorin as antigen
The antibody answered, wherein most widely used at present is Rapid plasma reagintest (RPR, Rapid Plasma
Reagin), this method is easy to operate, rapid, and test result is clearly readable, and easy to be quick, stability is good.Its principle is to utilize the heart
Phosphatide, lecithin and cholesterol composition mixture are adsorbed with special active carbon particle, are observed by the naked eye as antigen
Occur on white card boards whether there is or not black agglutinating particle and directly carries out result judgement.TP antigen plasma assay is to be directed to
As the microspironema pallidum specific component of antigen, therefore it is used for screening and makes a definite diagnosis syphilis.The agglutination of microspironema pallidum gelatin
Experiment (TPPA) is coated on the exquisite bacterial strain ingredient of pathogenic T P on artificial carrier's gelatine particle, and it is corresponding to detect syphilis in blood plasma
Antibody, since reagent preparation process eliminates various nonspecific reactions, sensibility and specificity is higher, is main at present
TP antigen plasma assay.
Examination of cerebrospinal fluid mainly includes CSF-RPR, CSF white blood cell count(WBC) or protein level.CSF-RPR and blood plasma RPR is former
Manage identical, specificity and cerebrospinal fluid Venereal Disease Research Laboratory (VDRL, Venereal Disease Research
Laboratory) test (CSF-VDRL) is similar, but sensibility ratio CSF-VDRL high, is currently used cerebrospinal fluid syphilis spiral shell
The test of body non-specific antibody is revolved, general CSF-RPR is positive, i.e., diagnosable neurolues.The important reference indicator of neurolues
It further include that cerebrospinal fluid cell count or protein level are levied when CSF-RPR is negative findings if there is neurolues clinic
As the detection of, blood plasma is positive and cerebrospinal fluid cell count (CSF white blood cell count(WBC) > 5/ μ l be it is abnormal, for merging HIV
The patient of infection, cerebrospinal fluid cell count can be higher, to improve diagnostic accuracy, this kind of Cerebrospinal Fluid in Patients cell count exception
Standard should rise to leucocyte > 20/ μ l) and/or protein level exception, it may be considered that it is diagnosed as neurolues.
Multinomial clinical research confirmation, protein content elevated-levels and coincident with severity degree of condition in Neurosyphilis cerebrospinal fluid
It is positively correlated, it is negatively correlated with prognosis at a specified future date；Oligoclonal band (OCB) is positive in Neurosyphilis cerebrospinal fluid, cerebrospinal fluid tau
Protein content raising or CXCL13 raising etc. prompt that immune response has occurred in central nervous system.But at present not
The biological markers of believable reflection neurolues neurotrosis degree.Therefore, find assessment Neurosyphilis nerve by
Damage degree and the index of prognosis are particularly important.
Nerve cell axon is by 3 kinds of skelemin, that is, microfilaments, micro-pipe and median fiber (intermediate
Filaments, IFs) composition complexed network system, it determines the shape, intensity, supporting role of cell, and transports in cell
Dynamic, vesicular traffic, cell division play an important role in signal transduction.Median fiber is a kind of hollow fibre structure, and diameter is
10nm is broadly divided into six class such as neurofilament protein and keratin between micro-pipe and microfilament.Median fiber has nucleus
Fixed function provides mechanical strength to cell, participates in cell connection, work to intracellular matter transport, participate in cell division
Activity, participation information transduction activity etc..
Neurofilament protein is only expressed in nerve cell, including neurofilament protein light chain (Neurofilament-Light, NF-
L), chain (Neurofilament-Medium, NF-M), neurofilament protein heavy chain (Neurofilament- in neurofilament protein
Heavy, NF-H) three kinds of substructures；Its structure is similar with other median fibers, the rod-shaped area including head amino area, α spiral with
And tail portion carboxyl area.The effect of neurofilament protein is to stablize the form of axon, the conduction speed for keeping its diameter and maintaining its stable
Degree, and play a role during neuron differentiation, axon growth and regenerative process etc..
It is reported that there are many marker for being able to reflect central lesion, such as amyloid beta-protein precursor and β starch
Sample albumen, MBP ELISA, neuronspecific enolase, microtubule associated protein tau etc., neurolues there are also
Variation, but all there is a problem of that specificity is not strong etc. such.Neurofilament protein is in amyotrophic lateral sclerosis
(amyotrophic lateral sclerosis, ALS), Parkinson's disease (Parkinson ' s disease, PD), the sea A Erzi
Silent disease (Alzheim er ' s disease, AD), peroneal muscular atrophy (Charcot-Marie-Tooth disease, CMT),
Neuron intermediate filament inclusion disease (neuronal intermediate filament inclusion disease, NIFID),
Diabetic neuropathy (diabetic neuropathy), spinal muscular atrophy (spinal muscular atrophy) etc.
It is all changed in disease, thus it is speculated that the exception of neurofilament protein is related with a variety of the nervous system diseases, but its cellular elements machine
It makes unclear.
NF-L is the substructure being expressed at first in neurofilament protein, molecular weight 68kDa.NF-H is also composition neurofilament
One of main component of albumen, molecular weight 205kDa are finally expressed neurofilament protein, axon diameter and are mentioned with amplification
High axon conduction of velocity is directly related.It is reported that the expression of NF-L and NF-H is independent from each other, this may with they
Genome positioning is different related.
The c-terminus of NF-H has the site of 51 phosphorylations, proximally arrives distal end, and phosphorylation degree is different.In neural cellular
In body or dendron, NF-H exists without phosphorylation substantially, and in neuron axon, then the i.e. phosphorylation mostly in the form of phosphorylation
Neurofilament protein heavy chain (phosphorylated Neurofilament-Heavy, pNF-H) exists, and NF-H is for stablizing axis
The conduction of rope form and nerve signal plays an important role.
Summary of the invention
First aspect present invention provides a kind of Lues Assay kit, and the kit includes for detecting blood NF-L water
Flat detection reagent.
Second aspect of the present invention provides a kind of detection reagent for detecting blood NF-L and is preparing Nerve Testing kit
In application.
The present inventor by studying NF-L level in Neurosyphilis blood, find for the first time blood NF-L it is abnormal with
The development of neurolues and it is related indication there are certain correlations, thus there is great clinical anticipate for neurolues
Justice.Due to there is symptom Neurosyphilis group blood NF-L difference compared with asymptomatic neurosyphilis patient group blood NF-L to have statistics
Meaning is learned, illustrates that the protein molecular level in different clinical classifications or by stages Neurosyphilis cerebrospinal fluid is different, patient
Protein molecular level in cerebrospinal fluid is different, is immunoreacted degree and immunologic mjury degree is also different, therefore can basis
Its protein molecular level easily early diagnoses syphilis, parting by stages, therapeutic evaluation and/or prognosis evaluation.
Detailed description of the invention
Fig. 1 is -2015 years syphilis disease incidence (1/,100,000) of China in 2006.Note: 12.80,2007 2006 15.88,
30.44,2013 29.47,2012 26.86,2011 23.07,2010 19.49,2009 2008 30.04,2014
30.93,2015 31.85 year.
Fig. 2 shows the NF-L analysis result of each group blood samples of patients.Wherein, NS indicates symptom neurolues group (n=
20)；ANS indicates asymptomatic neurosyphilis group (n=46)；S indicates latent syphilis group (n=18).
Fig. 3 shows that the average blood NF-L of each group patient is horizontal.Wherein, NS indicates symptom neurolues group (n=
13)；ANS indicates asymptomatic neurosyphilis group (n=46, including 27 positive (+) patients of cerebrospinal fluid TRUST and 19 cerebrospinal fluid
TRUST feminine gender (-) patient)；S indicates latent syphilis group (n=18).
Specific embodiment
To make the object, technical solutions and advantages of the present invention clearer, below in conjunction with the embodiment of the present invention to this hair
Bright technical solution is clearly and completely described.But described embodiment is a part of the embodiments of the present invention, and
The embodiment being not all of.Based on the embodiments of the present invention, those of ordinary skill in the art are not making creative work
Under the premise of every other embodiment obtained, shall fall within the protection scope of the present invention.
First aspect present invention provides a kind of Lues Assay kit, and the kit includes for detecting blood NF-L water
Flat detection reagent.Preferably, the syphilis is neurolues, more preferably there is symptom neurolues.
In some preferred embodiments, the detection reagent is for carrying out qualitative detection or quantitative inspection to blood NF-L
The detection reagent of survey.It is further preferred that the detection reagent is the detection reagent for carrying out quantitative detection to blood NF-L.
In some preferred embodiments, the blood NF-L level is blood NF-L protein level, it is further preferred that described
Detection reagent is the antibody of anti-NF-L, it is further preferred that, the antibody is the antibody of anti-human NF-L, still more preferably
It is that the antibody is polyclonal antibody or monoclonal antibody, most preferably monoclonal antibody.The monoclonal antibody can be
Know, for example, from commercial reagents company (such as R&D Systems, Inc., GeneTex International Corporation,
Abcam etc.) monoclonal antibody bought, or wrapped from the enzyme linked diagnostic kit of NF-L that the companies such as German IBL buy
The monoclonal antibody included.
In some preferred embodiments, the kit further includes optional second detection reagent, second inspection
Test agent is for examining selected from VDRL (venereal disease research laboratory (Venereal Disease Research Laboratory))
It surveys, USR (unheated serum regain (reagin that blood plasma is not required to heating)) detection, TRUST (toluidine red
Unheated serum test (toluidine red blood plasma is not required to heat run)) detection, (rapid plasma regain is (fast by RPR
Fast blood plasma reagin)) detection, FTA-ABS (fluorescent treponemal antibody-absorption (fluorescence spiral shell
Revolve body Absorption of antibody)) detection, TPHA (Treponema pallidum hemagglutination assay (microspironema pallidum
Hemagglutination test)) detection, TPPA (Treponema pallidum particle agglutination assay (treponemal
Body particle agglutination test) detection, ELISA (enzyme-linked immuno-sorbent assay (Enzyme-linked Immunosorbent Assay examination
Test) it detects, the one or more kinds of syphilis for the group that cerebrospinal fluid NF-L is detected, blood pNF-H is detected, cerebrospinal fluid pNF-H detection forms
The detection reagent of detection method, these Lues Assay methods and its reagent used are all known.For example, VDRL detection, USR
Detection, TRUST detection, RPR detection, FTA-ABS detection, TPHA detection, TPPA detection and ELISA detection and its used examination
Agent can be described in professional standard such as controller used in syphilis diagnosis standard (WS 273-2007).The detection reagent of blood or cerebrospinal fluid NF-L can be with
Such as commercial kits(Neurofilament light)ELISA(Enzyme immunoassay for
quanlitative determination of human Neurofilament light(NF-L)protein in
Cerebrosphinal fluid) (LBL international GME) described, and the detection reagent of blood or cerebrospinal fluid pNF-H can
With such as commercial kits Human Phosphorylated Neurofilament H ELISA kit (BioVendor-
Laboratorn í medic í na a.s.) it is described.It is further preferred that second detection reagent be for selected from by RPR detection,
TPPA or TPHA detection, FTA-ABS detection, cerebrospinal fluid NF-L is detected, blood pNF-H is detected, the group of cerebrospinal fluid pNF-H detection composition
Lues Assay method detection reagent；It may further be preferable that second detection reagent be for FTA-ABS detection and/
Or the detection reagent of TPPA detection.FTA-ABS and TPPA is Diagnosis of Syphilis spirochaete infection specific index, it is considered that brain
Spinal fluid FTA-ABS feminine gender can exclude neurolues, the index combination NF-L testing result, can increase diagnosis neurolues
Sensibility and specificity.
In some preferred embodiments, the kit further includes for assisting the antibody of anti-NF-L to pass through ELISA
The auxiliary reagent of detection method detection blood NF-L.In some preferred embodiments, the auxiliary reagent includes selected from by NF-L
Antibody is coated with microtitre lath, NF-L antibody-solutions, horseradish peroxidase conjugate solution, NF-L protein standard sample, dilution
The group of buffer, cleaning solution, substrate solution, terminate liquid composition.
In some preferred embodiments, the kit further includes blood collection instrument, anticoagulant blood-collecting pipe and/or rush
Solidifying heparin tube.The blood collection instrument can be used to acquire whole blood from patient or suspected patient；The anticoagulant blood-collecting pipe can
To be used to be prepred by whole blood test plasma；The solidifying heparin tube of rush can be used to be prepred by whole blood serum.In the present invention, to be measured
Biological sample can be blood sample, more preferably blood plasma or serum.The blood collection instrument, anticoagulant blood-collecting pipe and/
Or promote solidifying heparin tube be all it is known in the art and common, those skilled in the art are used to implement this hair in selection of having the ability
It is bright.
Second aspect of the present invention provides the first detection reagent and optional second detection reagent for detecting blood NF-L
Application in preparation detection kit.
First detection reagent can be as described in the first aspect of the invention.For example, first detection reagent can be
For carrying out the detection reagent of quantitative detection or qualitative detection to blood NF-L, for example, the detection kit is for passing through
ELISA detection method carries out qualitative or quantitative detection detection kit to the NF-L in blood sample.It is further preferred that described
Detection reagent is the antibody of anti-NF-L, it is further preferred that, the antibody can be the antibody of anti-human NF-L；It is further excellent
Choosing, the antibody are monoclonal antibody.The monoclonal antibody can be as described above.
Second detection reagent can be for for detecting selected from horizontal by cerebrospinal fluid NF-L, cerebrospinal fluid pNF-H is horizontal, brain
Before spinal fluid RPR titre, blood RPR titre, cerebrospinal fluid leucocyte, cerebrospinal fluid protein, treatment and treatment after blood NF-L difference, treatment
The detection of the index of the group of cerebrospinal fluid pNF-H difference composition tries before cerebrospinal fluid NF-L difference, treatment and after treatment after preceding and treatment
Agent.
In some preferred embodiments, the kit be for being early diagnosed to neurolues, parting point
The kit of phase, therapeutic evaluation and/or prognosis evaluation.
(including early diagnosis, parting by stages, therapeutic evaluation and/or prognosis evaluation etc.) is being diagnosed to neurolues
When, parting can be carried out to Neurosyphilis according to blood NF-L level and by stages (parting be carried out to neurolues and/or is divided
Phase)；Alternatively, can be carried out relative to the difference of (or for treatment before) before pre- to Neurosyphilis according to blood NF-L prognosis pre-
After assess.Then, in some specific embodiments, the present invention provides a kind of Lues Assay kit, the kits
Including the detection reagent for detecting blood NF-L level, and for carrying out parting by stages or prognosis is commented to Neurosyphilis
Estimate.The present invention also provides the detection reagent in preparation for carrying out parting by stages (i.e. to neural plum to Neurosyphilis
Poison carries out parting and/or by stages) or the kit of prognosis evaluation in application.
(including early diagnosis, parting by stages, therapeutic evaluation and/or prognosis evaluation etc.) is being diagnosed to neurolues
When, can by blood NF-L level independently or with selected from horizontal by cerebrospinal fluid NF-L, cerebrospinal fluid pNF-H is horizontal, cerebrospinal fluid RPR
It before blood NF-L difference, treatment and is controlled before titre, blood RPR titre, cerebrospinal fluid leucocyte, cerebrospinal fluid protein, treatment and after treatment
After treatment before cerebrospinal fluid NF-L difference, treatment and treatment after cerebrospinal fluid pNF-H difference form group in one or more index knot
Close ground for being early diagnosed to neurolues, parting by stages, therapeutic evaluation and/or prognosis evaluation.Then, some specific
Embodiment in, the present invention provides a kind of Lues Assay kit, the kit includes: horizontal for detecting blood NF-L
The first detection reagent；Optional second detection reagent, second detection reagent is for detecting selected from by cerebrospinal fluid NF-L water
Before flat, cerebrospinal fluid pNF-H level, cerebrospinal fluid RPR titre, blood RPR titre, cerebrospinal fluid leucocyte, cerebrospinal fluid protein, treatment and
Cerebrospinal fluid pNF-H difference group before blood NF-L difference, treatment and after treatment before cerebrospinal fluid NF-L difference, treatment and after treatment after treatment
At group in one or more index.The present invention also provides first detection reagent and/or the second detection examinations
Agent preparation for being early diagnosed to neurolues, parting by stages, the detection kit of therapeutic evaluation and/or prognosis evaluation
In application.
In the present invention, blood NF-L is horizontal, cerebrospinal fluid NF-L is horizontal, cerebrospinal fluid pNF-H is horizontal, cerebrospinal fluid RPR titre, blood
Liquid RPR titre, cerebrospinal fluid leukocyte count, cerebrospinal fluid protein amount are detected by known detection method, before treatment and are controlled
Cerebrospinal fluid pNF-H difference all may be used before blood NF-L difference, treatment and after treatment before cerebrospinal fluid NF-L difference, treatment and after treatment after treatment
With the data calculation that is measured by known method.For example, NF-L, pNF-H can be measured using commercial kits, other refer to
Mark can the method according to as defined in China's professional standard controller used in syphilis diagnosis standard (WS 273-2007) measure.
Neurolues is that microspironema pallidum invades chronic infectious disease caused by central nervous system, can cause difficulty
It is the main reason for syphilis disables with the nervous system damage of recovery, therefore neurolues has become that seriously threaten the mankind strong
The disease of health.The present inventor has found after study, the development of blood NF-L level and neurolues and related indication exists
Certain correlation has symptom Neurosyphilis blood NF-L level difference compared with asymptomatic neurosyphilis patient to have statistics
Meaning illustrates that the protein molecular level of different clinical classifications or Neurosyphilis blood NF-L level by stages is different, is immunized
The extent of reaction and immunologic mjury degree are also different.
Neurofilament protein exists only in nerve cell, and Neuron-specific is strong, and has very strong resistance to enzymolysis energy
Power.After damaged nerve cell, NF-L can be discharged into blood.The present inventor is by grinding Neurosyphilis blood NF-L level
Study carefully, discovery blood NF-L level has great clinical meaning, and explores its Correlative Influence Factors.Although cerebrospinal fluid is reaction nerve
The sensitive indicator that histopathology sexually revises is the optimal selection of biological markers, but its target user's narrow range and is had
There is certain potential risk, therefore the present inventor analyzes NF-L level level in blood and its can with the correlation of other factors
With for neurolues early diagnosis, parting by stages, therapeutic evaluation and/or prognosis evaluation reliably and effectively technical side is provided
Case.
Embodiment
1, the general clinical data of patient
This research is total to patient in group 92, and median age is 37.5 years old, and the oldest value is 68 years old, minimum value 17
Year.It is to have symptom neurolues group, asymptomatic neurosyphilis and recessive plum according to WS 273-2007 controller used in syphilis diagnosis standard diagnostics
Poison.Wherein, there is symptom neurolues group 23；Asymptomatic neurosyphilis group 51；Latent syphilis control group 18.
There are symptom neurolues group male 17, women 6；Median age is 54 years old, the oldest value 66 years old, the age
Minimum value 32 years old；It married 20, unmarried 1, divorces 1, is bereft of one's spouse 1.Blood plasma TPPA total positives；Blood plasma RPR titre 1:1 suffers from
Person 1,1:4 patient 2,1:8 patient 2,1:16 patient 3,1:32 patient 4,1:64 patient 4,1:128 patient 2,
1:256 patient 5.Cerebrospinal fluid TPPA is 23 positive；Cerebrospinal fluid RPR titre is 1 negative, and 1:1 patient 6,1:2 patient 3,1:
4 patients 5,1:8 patient 3,1:16 patient 4,1:32 patient 1.Cerebrospinal fluid protein median is 62.3mg/dl, maximum
Value is 191.6mg/dl, minimum value 30mg/dl.Cerebrospinal fluid leukocyte count median is 17 × 106/ L, maximum value be 130 ×
106/ L, minimum value are 0 × 106/L。
Asymptomatic neurosyphilis group male 22, women 29；Median age is 33 years old, the oldest value 68 years old, year
Age minimum value 24 years old；It married 36, unmarried 12, divorces 3.Blood plasma TPPA total positives；Blood plasma RPR titre 1:1 patient 2
Example, 1:2 patient 3,1:4 patient 5,1:8 patient 11,1:16 patient 11,1:32 patient 14,1:64 patient 2,1:
128 patients 2,1:256 patient 1.Cerebrospinal fluid TPPA is 44 positive, 7 negative.Cerebrospinal fluid RPR titre is 30 negative, 1:1
Patient 9,1:2 patient 9,1:4 patient 2,1:8 patient 1.Cerebrospinal fluid protein median is 29.6mg/dl, and maximum value is
60.7mg/dl, minimum value 7.2mg/dl.Cerebrospinal fluid leukocyte count median is 10 × 106/ L, maximum value are 216 × 106/ L,
Minimum value is 1 × 106/L。
Latent syphilis group male 8, women 10；Median age is 32 years old, and the oldest value is 52 years old, and the age is minimum
Value is 17 years old；Married 12, unmarried 6.Blood plasma TPPA total positives；Blood plasma RPR titre negative patient 3,1:1 patient 1,
1:2 patient 3,1:4 patient 3,1:8 patient 2,1:16 patient 3,1:32 patient 1,1:64 patient 1,1:128 suffers from
Person 1.Cerebrospinal fluid TPPA is 17 negative, 1 positive；Cerebrospinal fluid RPR titre total negative.Cerebrospinal fluid protein median is
22.8mg/dl, maximum value 45.2mg/dl, minimum value 8.6mg/dl；Cerebrospinal fluid leukocyte count median is 3 × 106/ L,
Maximum value 5 × 106/ L, minimum value are 0 × 106/L.Specific data are as shown in table 1.
The general clinical data table of 1 patient of table
2, sample obtains
According to patient in group's situation, cerebrospinal fluid, blood progress routine are left and taken in row lumbar puncture art and ulnar vein centesis
It examines, and leaves and takes cerebrospinal fluid and blood preparation, sample is saved with opposed -80 DEG C of refrigerators, is finally unified detection, is avoided pattern detection
Batch error.
Under patient's informed consent, waist, which is worn, collects cerebrospinal fluid mark 5ml, venous collection blood preparation 10ml.Lumbar puncture art
After collecting cerebrospinal fluid, dispensed with cryopreservation tube, coded markings；It after venipuncture collects blood, is placed in 4 DEG C of centrifuges, is centrifuged
It 10 minutes, 3000 revs/min, is rapidly separated the limpid blood plasma in upper layer and is placed in cryopreservation tube, coded markings.Cerebrospinal fluid and plasma specimen
- 80 DEG C of refrigerators all are stored in, finally unify detection.
3, detection method
Detection method used in the examples is all known.Wherein, the detection of blood NF-L and cerebrospinal fluid NF-L use(Neurofilament light)ELISA(Enzyme immunoassay for quanlitative
determination of human Neurofilament light(NF-L)protein in cerebrosphinal
Fluid) (LBL international GME) is detected according to specification.The detection of blood plasma and cerebrospinal fluid pNF-H use
Human Phosphorylated Neurofilament H ELISA kit (BioVendor-Laboratorn í medic í
Na a.s.) and detected according to the specification of appended producer.Blood plasma RPR titre, cerebrospinal fluid RPR titre, brain Protein Detection
Detection method according to WS 273-2007 with brain leucocyte carries out.
4, therapeutic scheme
There is the treatment method of symptom neurolues and asymptomatic neurosyphilis using national standard treatment method, penicillin
24000000 U/ days, it is divided into 4,000,000 U/4 hours, intravenous drip, continuous treatment 14 days.Data are used in front for the treatment of before treating
The data that the 0th day sample detection obtained obtains；Data are the 180th day after being treated using above-mentioned therapeutic scheme after treatment
The result that the sample detection of acquirement obtains.
5, result and analysis
Each group patient's blood NF-L level and comparison in difference
The data (table 2) and comparative analysis (Fig. 2) result of the blood NF-L level of each group patient are as follows: having symptom neurolues
Group, asymptomatic neurosyphilis group, latent syphilis group patient the median of blood NF-L be respectively 207.89pg/ml, 188.53pg/
Ml, 204.1pg/ml, wherein there is symptom neurolues group blood NF-L level to be higher than asymptomatic neurosyphilis group (P < 0.001), tool
It is statistically significant.Although having symptom neurolues group blood NF-L is horizontal to be higher than latent syphilis group, it is not statistically significant
(P=0.063).Asymptomatic neurosyphilis group, the blood NF-L level of latent syphilis group patient do not have difference (P=0.552).Cause
This, can carry out parting or by stages to Neurosyphilis according to blood NF-L level, such as will have symptom neurolues to be different from
Asymptomatic neurosyphilis group.
In addition, there is the blood NF-L level of symptom neurolues group (NS) patient to be significantly higher than asymptomatic neurosyphilis group
(ANS) and the level of stealthy syphilis group (S) patient.There are symptom neurolues group (NS) patient and asymptomatic neurosyphilis group
(ANS) after penicillin standard regimens are treated, blood NF-L level is remarkably decreased (referring to Fig. 3) patient.
2 each group patient's blood NF-L of table is horizontal (n=84)
| Disease type | NF-L level (pg/ml) (median minimum value, maximum value)) |
| There are symptom neurolues (20) | 207.89(146.70,1897.86) |
| Asymptomatic neurosyphilis (46) | 188.53(91.41,3434.74) |
| Stealthy syphilis (18) | 204.1(90.9,594.91) |
The correlation analysis of blood NF-L and each factor
It is horizontal further to have detected cerebrospinal fluid NF-L and pNF-H, has in addition also carried out blood RPR detection (result such as the following table 3
Shown in 4).
3 each group Cerebrospinal Fluid in Patients NF-L of table is horizontal (n=92)
| Disease type | NF-L level (pg/ml) (median minimum value, maximum value)) |
| There are symptom neurolues (23) | 5806.25(409.25,41616.68) |
| Asymptomatic neurosyphilis (51) | 217.59(33.48,2020.43) |
| Latent syphilis (18) | 266.32(117.83,679.43) |
4 each group Cerebrospinal Fluid in Patients pNF-H of table is horizontal (n=92)
| Disease type | PNF-H level (pg/ml) (median minimum value, maximum value)) |
| There are symptom neurolues (23) | 986.46(117.26,9018.81) |
| Asymptomatic neurosyphilis (51) | 43(0,196.53) |
| Latent syphilis (18) | 48.71(0,199.05) |
Carry out correlation analysis discovery to all patient's blood NF-L testing results: blood NF-L level and cerebrospinal fluid NF-L are horizontal
(r=0.257, P < 0.018)；Horizontal (r=0.544, P < 0.001) the significant correlation of cerebrospinal fluid pNF-H.It therefore, can be by blood NF-
L level independently or with cerebrospinal fluid NF-L, cerebrospinal fluid pNF-H horizontal integration for the early diagnosis of neurolues, parting
By stages, therapeutic evaluation and/or prognosis evaluation.
Embodiment 3: blood NF-L prognostic analysis
Prognosis is total to 25 people of follow-up, there is 15 people of symptom neurolues group follow-up, 10 people of asymptomatic neurosyphilis group.Specific test
Index and statistical result see the table below 5.
By that will there is symptom neurolues group and the pretherapy and post-treatment difference of asymptomatic neurosyphilis group blood NF-L (to count after treatment
Numerical value before value-treatment) comparison in difference discovery, the horizontal prognosis difference median of neurolues group blood NF-L be -3.48pg/ml,
Decline 3.48pg/ml；Difference median is 2.36pg/ml before and after asymptomatic neurosyphilis group blood NF-L horizontal stretcher, i.e., on
Rise 2.36pg/ml；The two comparing difference is statistically significant (P=0.03).It therefore, can be according to the pretherapy and post-treatment difference of blood NF-L
Prognosis evaluation is carried out to Neurosyphilis.
The correlation analysis of prognosis blood NF-L and each factor
Correlation analysis discovery is carried out to blood NF-L level after treatment, blood NF-L level and syphilis (r=- by stages after treatment
0.503, P=0.017) horizontal (r=0.687, P < 0.001), cerebrospinal fluid RPR titre (r=0.505, P=blood NF-L before, treating
0.017), brain albumen (r=0.607, P=0.003) is related.Therefore, can by blood NF-L level after treatment independently or with
It is used for neurolues in combination selected from the index by the group that blood NF-L level, cerebrospinal fluid RPR titre, brain albumen form before treating
Early diagnosis, parting by stages, therapeutic evaluation and/or prognosis evaluation.
Blood plasma pNF-H level (r=-0.595, P=after pretherapy and post-treatment blood NF-L change level (i.e. prognosis difference) and treatment
0.003) cerebrospinal fluid NF-L level (r=- before cerebrospinal fluid NF-L horizontal (r=-0.636, P=0.001), treatment after, treating
0.683, P < 0.001) cerebrospinal fluid pNF-H horizontal (r=-0.559, P=0.007) is related before, treating.Therefore, it can will treat
Front and back blood NF-L change level independently or with selected from horizontal by prognosis blood plasma pNF-H, prognosis cerebrospinal fluid NF-L is horizontal, treatment
The index for the group that preceding cerebrospinal fluid NF-L is horizontal, treats preceding cerebrospinal fluid pNF-H level composition is used for the early stage of neurolues in combination
Diagnosis, parting by stages, therapeutic evaluation and/or prognosis evaluation.
Table 5 has symptom neurolues group and asymptomatic neurosyphilis group blood NF-L horizontal variation table before and after treatment
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention, rather than its limitations；Although
Present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that: it still may be used
To modify the technical solutions described in the foregoing embodiments or equivalent replacement of some of the technical features；
And these are modified or replaceed, technical solution of various embodiments of the present invention that it does not separate the essence of the corresponding technical solution spirit and
Range.
Claims (10)
1. a kind of Lues Assay kit, which is characterized in that the kit includes for detecting blood neurofilament protein light chain
Horizontal detection reagent.
2. kit according to claim 1, which is characterized in that the detection reagent is for blood neurofilament protein
Light chain carries out the detection reagent of qualitative detection or quantitative detection.
3. kit according to claim 1, which is characterized in that the detection reagent is the anti-of anti-neurofilament protein light chain
Body；Preferably, the antibody is the antibody of anti human nerve silk-fibroin light chain；Also it is preferred that the antibody is polyclonal
Antibody or monoclonal antibody, most preferably monoclonal antibody.
4. kit according to claim 1, which is characterized in that the kit further includes the second detection reagent, described
Second detection reagent is for selected from VDRL detection, USR detection, TRUST detection, RPR detection, TPHA or TPPA detection, FTA-
ABS detection, ELISA detection, cerebrospinal fluid NF-L detection, blood pNF-H detection, cerebrospinal fluid pNF-H detection composition group one kind or
The detection reagent of a variety of Lues Assay methods of person；Preferably, second detection reagent be for selected from by RPR detection,
TPHA or TPPA detection, FTA-ABS detection, cerebrospinal fluid NF-L is detected, blood pNF-H is detected, the group of cerebrospinal fluid pNF-H detection composition
Lues Assay method detection reagent；It is further preferred that second detection reagent be for FTA-ABS detection and/or
The detection reagent of TPPA detection.
5. kit according to claim 4, which is characterized in that the kit further includes for assisting anti-neurofilament egg
The antibody of white light chain detects the auxiliary reagent of blood neurofilament protein light chain by ELISA detection method；Preferably, the auxiliary
Reagent includes selected from by neurofilament protein light chain antibody coating microtitre lath, neurofilament protein light chain antibody solution, horseradish mistake
Oxidizing ferment conjugate solution, neurofilament protein light chain protein standard sample, dilution buffer, cleaning solution, substrate solution, terminate liquid
The group of composition.
6. kit according to claim 5, it is characterised in that:
The kit further includes blood collection instrument, anticoagulant blood-collecting pipe and/or promotees to coagulate heparin tube；And/or
The syphilis is neurolues, more preferably there is symptom neurolues.
7. the first detection reagent and optional second detection reagent for detecting blood neurofilament protein light chain are in preparation right
It is required that the application in kit described in any one of 1 to 6.
8. application according to claim 7, which is characterized in that the detection kit is for passing through ELISA detection method
Qualitative or quantitative detection detection kit is carried out to the neurofilament protein light chain in blood sample.
9. application according to claim 7 or 8, it is characterised in that:
First detection reagent is that the detection for carrying out quantitative detection or qualitative detection to blood neurofilament protein light chain tries
Agent；
It is further preferred that the detection reagent is the antibody of anti-neurofilament protein light chain；
It may further be preferable that the antibody is the antibody of anti human nerve silk-fibroin light chain；
It is even furthermore preferable that the antibody is monoclonal antibody.
10. application according to any one of claims 7 to 9, which is characterized in that the kit is used to carry out syphilis
Early diagnosis, parting by stages, therapeutic evaluation and/or prognosis evaluation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910444151.9A CN110133288A (en) | 2018-03-13 | 2018-03-26 | Application of the neurofilament protein light chain in syphilis blood testing |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810202837 | 2018-03-13 | ||
| CN201910444151.9A CN110133288A (en) | 2018-03-13 | 2018-03-26 | Application of the neurofilament protein light chain in syphilis blood testing |
| CN201810252711.6A CN108490191B (en) | 2018-03-13 | 2018-03-26 | Application of the neurofilament protein light chain in syphilis blood testing |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810252711.6A Division CN108490191B (en) | 2018-03-13 | 2018-03-26 | Application of the neurofilament protein light chain in syphilis blood testing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110133288A true CN110133288A (en) | 2019-08-16 |
Family
ID=63337773
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810252711.6A Active CN108490191B (en) | 2018-03-13 | 2018-03-26 | Application of the neurofilament protein light chain in syphilis blood testing |
| CN201910444151.9A Pending CN110133288A (en) | 2018-03-13 | 2018-03-26 | Application of the neurofilament protein light chain in syphilis blood testing |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810252711.6A Active CN108490191B (en) | 2018-03-13 | 2018-03-26 | Application of the neurofilament protein light chain in syphilis blood testing |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN108490191B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110531085A (en) * | 2019-08-30 | 2019-12-03 | 北京利德曼生化股份有限公司 | A kind of magnetic microparticle chemiluminescence detection kit and preparation method thereof measuring human nerve silk light chain protein content |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110456086B (en) * | 2019-08-02 | 2023-07-14 | 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） | Non-specific antibody quality control fixed value serum for syphilis, preparation method, application and kit for syphilis detection |
| CN116519953B (en) * | 2023-06-26 | 2023-09-15 | 首都医科大学附属北京地坛医院 | Application of EDA2R protein and specific antibody thereof in preparation of syphilis diagnosis product |
| CN117088976B (en) * | 2023-09-28 | 2024-03-08 | 北京凯祥弘康生物科技有限公司 | anti-NFL monoclonal antibody |
| CN117607432B (en) * | 2024-01-17 | 2024-04-09 | 首都医科大学附属北京地坛医院 | Application of MSR1 protein and specific antibody thereof in preparation of neural syphilis or neural injury diagnostic product |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102821777A (en) * | 2009-12-14 | 2012-12-12 | 昂热大学 | Use of a neurofilament peptide for the treatment of glioma |
| CN102918397A (en) * | 2010-04-01 | 2013-02-06 | 班扬生物标记公司 | Markers and assays for detection of neurotoxicity |
| CN106461645A (en) * | 2014-04-07 | 2017-02-22 | 铁马诊断公司 | Traumatic brain injury and neurodegenerative biomarkers, methods, and systems |
| CN106519028A (en) * | 2016-09-29 | 2017-03-22 | 厦门两易生物科技有限公司 | Method for detecting monoclonal antibody of neurofilament protein related polypeptide |
| CN107003317A (en) * | 2014-10-06 | 2017-08-01 | 日内瓦大学 | Biomarker and its application in brain damage |
| WO2017193119A1 (en) * | 2016-05-06 | 2017-11-09 | Duke University | Methods and kits for diagnosing and treating nervous system disease or injury |
-
2018
- 2018-03-26 CN CN201810252711.6A patent/CN108490191B/en active Active
- 2018-03-26 CN CN201910444151.9A patent/CN110133288A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102821777A (en) * | 2009-12-14 | 2012-12-12 | 昂热大学 | Use of a neurofilament peptide for the treatment of glioma |
| CN102918397A (en) * | 2010-04-01 | 2013-02-06 | 班扬生物标记公司 | Markers and assays for detection of neurotoxicity |
| CN106461645A (en) * | 2014-04-07 | 2017-02-22 | 铁马诊断公司 | Traumatic brain injury and neurodegenerative biomarkers, methods, and systems |
| CN107003317A (en) * | 2014-10-06 | 2017-08-01 | 日内瓦大学 | Biomarker and its application in brain damage |
| WO2017193119A1 (en) * | 2016-05-06 | 2017-11-09 | Duke University | Methods and kits for diagnosing and treating nervous system disease or injury |
| CN106519028A (en) * | 2016-09-29 | 2017-03-22 | 厦门两易生物科技有限公司 | Method for detecting monoclonal antibody of neurofilament protein related polypeptide |
Non-Patent Citations (7)
| Title |
|---|
| EMILY L. HO ET AL.: "Neurosyphilis Increases Human Immunodeficiency Virus (HIV)-associated Central Nervous System Inflammation but Does Not Explain Cognitive Impairment in HIV-infected Individuals With Syphilis.", 《CLINICAL INFECTIOUS DISEASES》 * |
| ROSENGREN L.E.ET AL.: "Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF.", 《JOURNAL OF NEUROCHEMISTRY》 * |
| SAHRA ABDULLE ET AL.: "CSF neurofilament protein (NFL) – a marker of active HIV-related neurodegeneration.", 《J NEUROL》 * |
| W.J.A. VAN GEEL ET AL.: "An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid.", 《JOURNAL OF IMMUNOLOGICAL METHODS》 * |
| 中华人民共和国卫生部: "《中华人民共和国卫生行业标准WS 273-2007》", 17 April 2007 * |
| 国家技术监督局: "《中华人民共和国国家标准GB 15974-1995》", 23 January 1996 * |
| 王拥军 主编。: "《神经内科学高级教程 精装珍藏本》", 30 June 2016, 中华医学电子音像出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110531085A (en) * | 2019-08-30 | 2019-12-03 | 北京利德曼生化股份有限公司 | A kind of magnetic microparticle chemiluminescence detection kit and preparation method thereof measuring human nerve silk light chain protein content |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108490191B (en) | 2019-04-16 |
| CN108490191A (en) | 2018-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108490191B (en) | Application of the neurofilament protein light chain in syphilis blood testing | |
| CN108445232B (en) | Application of the NF-L in the detection of neurolues cerebrospinal fluid | |
| Lövheim et al. | Reactivated herpes simplex infection increases the risk of Alzheimer's disease | |
| CN1339108A (en) | Method for diagnosing and distinguishing stroke | |
| Ayele et al. | Evaluation of circulating cathodic antigen (CCA) strip for diagnosis of urinary schistosomiasis in Hassoba school children, Afar, Ethiopia | |
| Rider et al. | Idiopathic inflammatory muscle disease: clinical aspects | |
| CN108490176B (en) | Application of the phosphorylated neurofilament ferritin heavy chain in Lues Assay | |
| CN103823069B (en) | Specificity IgE biologic activity detection method and the test kit used thereof | |
| CN114994327A (en) | Application of biomarker GSDME | |
| CN108196051B (en) | The application of Lues Assay kit and the reagent comprising CD14 detection reagent in Lues Assay | |
| Villacieros‐Álvarez et al. | Myelin oligodendrocyte glycoprotein antibodies in adults with a first demyelinating event suggestive of multiple sclerosis | |
| JP6158825B2 (en) | Tenascin C and its use in rheumatoid arthritis | |
| JP5339227B2 (en) | Acrolein, interleukin-6 and CRP content, polyamine oxidase activity or polyamine oxidase protein mass, and method for detecting stroke / asymptomatic cerebral infarction using subject's age as an index | |
| CN108535479B (en) | Application of the sCD163 detection reagent in Lues Assay and the kit including the reagent | |
| Råstam et al. | Population screening and referral for hypercholesterolemia | |
| CN108414741A (en) | A kind of purposes of immune composition in preparing membranous nephropathy Non-invasive detection reagent | |
| CN117805391A (en) | Biomarker for detecting early mild cognitive impairment and/or Alzheimer's disease and application thereof | |
| Ammitzbøll et al. | NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis | |
| RU2571500C1 (en) | Method for assessing non-specific body resistance in hip displasia in children | |
| Spicknall et al. | Relation of brucellosis and multiple sclerosis | |
| Abdulle et al. | SAT0471 Abnormal nailfold capillaroscopic patterns are common in underweight subjects with raynaud’s phenomenon | |
| UA140008U (en) | METHOD OF ASSESSING THE DEGREE OF ACUTE BACTERIAL MENINGITIS OF MENINGOCOCCAL ETIOLOGY | |
| CN117007822A (en) | Marker for screening risk of schizophrenia and application thereof | |
| RU2550664C1 (en) | Method for individual assessment of patients to establish fact of chronic cardiac insufficiency suffered | |
| CN118169396A (en) | Clinical application of sBCMA in cerebrospinal fluid in diagnosis and monitoring of autoimmune diseases of central nervous system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190816 |
|
| RJ01 | Rejection of invention patent application after publication |